Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

NCT01561586 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2019-02-27

No results posted yet for this study

Summary

Current standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiation (CRT). Although recently reported meta-analysis studies also demonstrated improved local control rates and survival with cisplatin-based chemotherapy concurrent to radiation therapy (RT), the optimal cisplatin dose and dosing schedule are still undetermined.

In light of the results of the previous clinical trial, weekly cisplatin 40 mg/m2 considered to be a standard regiment in cisplatin doses and dosing schedules. However, our randomized phase II trial showed that tri-weekly cisplatin 75mg/m2 has lower toxicities and a better outcome in locally advanced cervical cancer.

In this randomized phase III trial, the investigators investigate that there may be a survival difference between weekly cisplatin 40 mg/m2 and tri-weekly cisplatin 75 mg/m2 administration concurrent to RT in cervical cancer.

Conditions

Interventions

DRUG

Weekly cisplatin with RT

Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours. Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)

DRUG

Tri-weekly cisplatin with RT

Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute). Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day. External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER
  • Asan Medical Center

    collaborator OTHER
  • Gangnam Severance Hospital

    collaborator OTHER
  • Korea Cancer Center Hospital

    lead OTHER

Principal Investigators

  • SANG YOUNG SY RYU, M.D. · STAFF

  • SARIKAPAN WILAILAK, M.D. · Ramathibodi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2020-03-31
Completion
2023-03-31

Countries

  • China
  • South Korea
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561586 on ClinicalTrials.gov